BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21692933)

  • 21. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
    Papatheodoridis G; Goulis J; Manolakopoulos S; Margariti A; Exarchos X; Kokkonis G; Hadziyiannis E; Papaioannou C; Manesis E; Pectasides D; Akriviadis E
    J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.
    Chan HL; Wong GL; Tse CH; Chan HY; Wong VW
    J Infect Dis; 2011 Aug; 204(3):408-14. PubMed ID: 21742839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
    Wong GL; Wong VW; Choi PC; Chan AW; Chim AM; Yiu KK; Chu SH; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2011; 16(2):165-72. PubMed ID: 21447865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Early prediction of lamivudine response in e antigen-negative chronic hepatitis B patients].
    Li JG; Li JX; Liu MX; Qin HQ; Chai YY; Wang XY; Li SF; Tian SW; Zhao LF; Niu Q; Zhang JQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):745-9. PubMed ID: 19874689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time.
    Tai DI; Lin SM; Sheen IS; Chu CM; Lin DY; Liaw YF
    Hepatology; 2009 Jun; 49(6):1859-67. PubMed ID: 19378345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography.
    Wong GL; Wong VW; Choi PC; Chan AW; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Am J Gastroenterol; 2008 Dec; 103(12):3071-81. PubMed ID: 19086958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.
    Lin CL; Liao LY; Liu CJ; Yu MW; Chen PJ; Lai MY; Chen DS; Kao JH
    Hepatology; 2007 May; 45(5):1193-8. PubMed ID: 17464993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
    Kumar M; Sarin SK; Hissar S; Pande C; Sakhuja P; Sharma BC; Chauhan R; Bose S
    Gastroenterology; 2008 May; 134(5):1376-84. PubMed ID: 18471514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of spontaneous decline of HBV DNA in chronic hepatitis B patients in 12 weeks].
    He H; Xu ZN; Cai DC; Nai N; Ling N; Zeng WQ; Shi XF; Zhao YR; Zhou Z; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):271-4. PubMed ID: 19403025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Histological changes in the livers of chronic hepatitis B patients with persistently normal serum alanine transaminase levels].
    Gui HL; Xie Q; Wang H; Cai W; Lin ZM; Jiang S; Xu P; Zhou XQ; Guo Q; Yu H
    Zhonghua Gan Zang Bing Za Zhi; 2007 Dec; 15(12):881-5. PubMed ID: 18171518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
    N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.